MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Depreciation & Amortization 2011-2025 | BHC
Annual Depreciation & Amortization Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.26 B | 1.39 B | 1.55 B | 1.82 B | 2.08 B | 2.82 B | 2.86 B | 2.87 B | 2.47 B | 1.61 B | 2.02 B | 986 M | 613 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.87 B | 613 M | 1.87 B |
Quarterly Depreciation & Amortization Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 320 M | - | - | - | 319 M | - | 1.03 B | 699 M | 352 M | - | 1.19 B | 807 M | 403 M | - | 1.4 B | 961 M | 481 M | - | 1.58 B | 1.06 B | 532 M | - | 2.27 B | 1.57 B | 786 M | - | 2.04 B | 1.34 B | 674 M | - | 2.16 B | 1.45 B | 731 M | - | 726 M | 635 M | 407 M | - | 439 M | 408 M | 401 M | - | 946 M | 318 M | 341 M | - | 235 M | 222 M | 216 M | - | 155 M | 122 M | 127 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.27 B | 122 M | 786 M |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
8.75 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.21 | -7.63 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
125 M | $ 12.36 | -2.37 % | $ 633 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | $ 21.6 | 0.07 % | $ 2.06 B |  France |
 |
Evolus
EOLS
|
5.3 M | $ 6.88 | 0.36 % | $ 427 M | USA |
 |
Harrow Health
HROW
|
1.06 M | $ 50.08 | -0.16 % | $ 1.63 B | USA |
 |
China Pharma Holdings
CPHI
|
2.62 M | $ 1.29 | -1.56 % | $ 22.5 M |  China |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 5.36 | -8.71 % | $ 706 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 26.48 | 1.77 % | $ 1.22 B | USA |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.26 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 4.11 | -2.14 % | $ 57.8 M | USA |
 |
Rockwell Medical
RMTI
|
1.44 M | $ 0.87 | 7.18 % | $ 20.3 M | USA |
 |
Solid Biosciences
SLDB
|
2.46 M | $ 5.83 | -1.19 % | $ 238 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 3.63 | -0.41 % | $ 4.5 M | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
268 K | $ 2.37 | 1.28 % | $ 320 M | USA |
 |
Perrigo Company plc
PRGO
|
326 M | $ 13.87 | 0.95 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | $ 0.51 | -16.94 % | $ 8.08 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 4.5 | -2.21 % | $ 135 M | USA |
 |
cbdMD
YCBD
|
452 K | $ 1.69 | 3.68 % | $ 7.29 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
28.2 M | $ 9.92 | 0.22 % | $ 705 M | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
580 K | $ 0.58 | -1.87 % | $ 27.8 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
35.7 M | $ 9.6 | -5.43 % | $ 5.93 B | Canada |
 |
TherapeuticsMD
TXMD
|
922 K | $ 1.72 | 0.88 % | $ 18 M | USA |
 |
Viatris
VTRS
|
3.03 B | $ 12.33 | 0.69 % | $ 14.9 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |